Key result
Higher SERPINA3 linked to ~14% greater long-term mortality in suspected coronary chest pain without AMI.
Why the study?
SERPINA3 is upregulated after acute myocardial infarction, but data regarding its long-term prognostic value in myocardial infarction patients are scarce.
Does baseline SERPINA3 level predict long-term all-cause and cardiovascular mortality in patients hospitalized for chest pain of suspected coronary origin?
Cohort (n=871)
No
Does baseline SERPINA3 level predict long-term all-cause and cardiovascular mortality in patients hospitalized for chest pain of suspected coronary origin?
Hazard Ratio: 1.14 (95% CI 1.02–1.28)
p-value: p=0.022
Baseline SERPINA3 levels predict long-term all-cause mortality in patients presenting with chest pain without an acute myocardial infarction, but lack prognostic utility for atherothrombotic events or outcomes in AMI patients.
May support risk stratification in non-AMI chest pain; hypothesis-generating and requires prospective validation before clinical use.
INTRODUCTION: SERPINA3 is an acute-phase protein triggered by inflammation. It is upregulated after an acute myocardial infarction (AMI). Data on its long-term prognostic value in MI patients are scarce. We aimed to assess the utility of SERPINA3 as a prognostic marker in patients hospitalized for chest pain of suspected coronary origin. METHODS: A total of 871 consecutive patients, 386 diagnosed with AMI, were included. Stepwise Cox regression models, applying continuous loge-transformed values, were fitted for the biomarker with all-cause mortality and cardiac death within 2 years or all-cause mortality within the median 7 years as dependent variables. An analysis of MI and stroke, and combined endpoints, respectively, was added. The hazard ratio (HR) (95% CI) was assessed in a univariate and multivariable model. RESULTS: Plasma samples from 847 patients were available. By 2-year follow-up, 138 (15.8%) patients had died, of which 86 were cardiac deaths. The univariate analysis showed a significant association between SERPINA3 and all-cause mortality (HR 1.41 [95% 1.19-1.68], p < 0.001) but not for cardiac death. Associations after adjustment were non-significant. By 7-year follow-up, 332 (38.1%) patients had died. SERPINA3 was independently associated with all-cause mortality from the third year onward. The HR was 1.14 (95% CI, 1.02-1.28), p = 0.022. Similar results applied to combined endpoints, but not for MI and stroke, respectively. The prognostic value of SERPINA3 was limited to non-AMI patients. No independent associations were noted among AMI patients. CONCLUSIONS: SERPINA3 predicts long-term all-cause mortality but fails to predict outcome in AMI patients.
No takes yet. Share an insight, caveat, or question.
Nilsen et al. (2024) conducted a cohort in Chest pain of suspected coronary origin (n=871). SERPINA3 vs. Lower SERPINA3 levels was evaluated on All-cause mortality at 7 years (HR 1.14, 95% CI 1.02-1.28, p=0.022). Higher plasma levels of SERPINA3 were independently associated with long-term all-cause mortality (HR 1.14) in patients hospitalized for suspected coronary chest pain, though this prognostic value was limited to patients without acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: